January 4, 2019 8:17am
2018 proved that this is a short-term market, the RegMed sector will continue in a short-term game scenario and odds are to our universe's rebound
Pre-market indication: the oversold are back in the spotlight – 3 BUYs and 1 TRADE
Up early and about: CRISPR Therapeutics (CRSP) and Vertex Pharmaceuticals Incorporated (VRTX) announced that the U.S. FDA has granted Fast Track Designation for CTX001 for the treatment of sickle cell disease (SCD). CTX001 is an investigational, autologous, gene-edited hematopoietic stem cell therapy for patients suffering from severe hemoglobinopathies.
An indication can be a development of almost any kind. Specifically, it may be a confirmed fact, a possible fact, or an absence of something, a fragment of information or even an observation. The sole provision is that it provides insight to provide some vision into a likely course of action.
I answer one question, in which company should investors put, keep and commit their money!
A daily report may say little or a lot and its final judgement may be inconclusive; yet it serves as insurance that all indications are being examined and evaluated.
U.S. stock index futures are looking good
Dow futures are UP +1.24% (+282 points) and NASDAQ futures are UP +1.45% (+89 points)
U.S. stock index futures rose sharply on Friday to lead a strong rebound in biotech stocks.
European stocks rally as the US and China agree to hold trade talks
Asian markets were largely higher as investors cheered developments on the U.S.-China trade front.
Data docket: nonfarm payrolls out at 8.30 a.m., and unemployment data out at the same time.
- Investors will also be keeping an eye on a speech by Federal Reserve Chair Jerome Powell at 10:15 a.m. ET. Powell will take part in "Federal Reserve Chairs: Joint Interview" panel on monetary policy and central banking at the American Economic Association and Allied Social Science Association annual meeting in Atlanta, Georgia.
The iShares Nasdaq Biotechnology (IBB) is indicating a POSITIVE +1.29% UPSIDE
The SPDR S&P Biotech ETF (XBI) is NOT indicating a POSITIVE +1.46% UPSIDE
The Health Care Select Sector SPDR ETF (XLV) is indicating a POSITIVE +1.11% UPSIDE
The iShares Russell 2000 (IWM) is indicating a POSITIVE +1.29% UPSIDE
Investors and traders are STILL fighting this market with fear and increased uncertainty in this new quarter.
… But, a rebound is in store!
Last night’s closing post, “anxiety is piling on. Trading on Friday could get more volatile as the December jobs report is set for release tomorrow at 8:30 a.m. ET, while Fed chief Powell is set to take part in a panel discussion at 10:15 a.m. We might have turned the calendar but, we hop-scotched the trend in the sector.”
Last night’s percentage (%) indicators:
- Review the range of the 11 upside from +0.37% (KOOL) to +50.08% (HSGX +$0.06 to $0.18) while the 32 downside ranged from -0.13% (SAGE) to -14.77% (CLBS) with 2 flat closes (BSTG and RENE.L).
- 4 out of the 11 upside had higher (than the 3 month average) volume
- 12 out of the 32 downside experienced greater volume (than the 3 month average)
Tracking the closes:
In s sessions in January – there was 1 positive close and 1 negative close
Q4 and end-of-year:
- In 21 sessions in December – there were 8 positive close; 1 neutral, 2 market closes and 10 negative close;
- In 22 sessions in November – there were 1 holiday, 10 positive closes, 1 neutral and 10 negative closes;
- In 23 sessions in October – there were 17 negative closes and 6 positive sessions;
Companies in my headlights – It’s your decision; I provide an idea and context: I’d be BUYING …
CRISPER Therapeutics (CRSP) closed down -$1.85 to $28.02 after Wednesday’s +$1.30 to $29.87, Monday’s $1.82 to $28.57 and last Friday’s $26.75. CRISPR Therapeutics (CRSP) and Vertex Pharmaceuticals Incorporated (VRTX) today announced that the U.S. FDA has granted Fast Track Designation for CTX001 for the treatment of sickle cell disease (SCD). CTX001 is an investigational, autologous, gene-edited hematopoietic stem cell therapy for patients suffering from severe hemoglobinopathies. BUY with a positive +$0.48 or +1.71% pre-market indication. Be prepared for a share pricing UPSIDE;
Editas Medicine (EDIT) closed down -$1.38 to $21.96 after Wednesday’s +$0.59 to $23.34, Monday’s $2.03 to $22.75 and last Friday’s $20.72 - TRADE with a positive +$0.44 or +2% aftermarket indication. Be prepared for a share pricing UPSIDE;
Intellia Therapeutics (NTLA) closed down -$0.57 to $13.13 after Wednesday’s +$0.05 to $13.70, Monday’s $0.68 to $13.65 and last Friday’s $12.97 – TRADE;
Sangamo Therapeutics (SGMO) closed down -$0.74 to $11.04 after Wednesday’s +$0.30 (+2.61%) to $11.78, Monday’s $11.48 and Friday’s $10.86 and the previous Thursday’s $10.59. TRADE with a positive +$0.22 or +1.99% aftermarket indication. SELL to BUY;
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.